In a report issued on October 12, Vamil Divan from Credit Suisse maintained a Hold rating on AbbVie (NYSE: ABBV), with a price target of $85. The company’s shares closed on Friday at $90.69, close to its 52-week low of $85.24.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.6% and a 45.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Merck & Company.
Currently, the analyst consensus on AbbVie is a Hold with an average price target of $96.50, representing a 6.4% upside. In a report issued on October 2, Piper Jaffray also reiterated a Hold rating on the stock with a $100 price target.
.
See today’s analyst top recommended stocks >>
AbbVie’s market cap is currently $137.3B and has a P/E ratio of 22.45. The company has a Price to Book ratio of -40.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
